Developing new
medicines for orphan conditions is indeed a challenge from several perspectives
as we have been discussing in the previous articles of this blog. This link will take you
to a very recent short article (in English) which gives a historical summary of
the orphan drug market and how the pharma industry is moving to this new
frontier.
The following articles, while offering more information about the drug development environment, may also give insight in how Advocacy
Groups/Foundations/Parents can build up initiatives to make new medicines
available:
Beaulieu CL et al. Orphanet Journal of Rare Diseases 2012;7:39.
All of them are
free access.
No comments:
Post a Comment